We report a rare case of late recurrence of a giant cell tumour (GCT) of bone 16 years after curettage and cryosurgery treatment. A 46-year-old man presented with swelling and progressively worsening pain in the lateral aspect of his right distal femur. He had undergone 4 procedures elsewhere to manage a GCT of bone and its recurrence 16 to 23 years previously. He underwent en bloc resection with an adequate wide margin and reconstruction with prosthesis. At the one-year follow-up, there was no evidence of recurrence or metastasis.
INTRODUCTION
Giant cell tumours (GCT) of bone are locally aggressive but have limited metastases.
1 25% of recurrences occur within 6 months, 97% within Late recurrence of giant cell tumour of bone after curettage and adjuvant treatment: a case report 2 years, and 100% during the first 3 years.
1,2 Late local recurrence after 5 years is uncommon. [1] [2] [3] [4] [5] [6] [7] [8] The recurrence rate is high after curettage and bone grafting alone. 2, 9, 10 The recurrence rate depends on the thoroughness of the curettage and the effectiveness of any adjuvant treatment (to eradicate residual tumour cells), [11] [12] [13] [14] [15] including burring, [10] [11] [12] chemical cauterisation with phenol, alcohol, and H 2 O 2 , 2,11,12,16 cryosurgery with liquid nitrogen, 11, 12, 14, 17, 18 and the insertion of methylmethacrylate cement. 9, 11, 12, 15, 18, 19 Adjuvant treatment after curettage decreases the recurrence rate and renders some risk factors such as recurrent tumour, pathological fracture, and Campanacci grade III no longer significant. 11, 12 We report a rare case of late local recurrence of a GCT of bone 16 years after curettage and cryosurgery.
CASE REPORT
In August 2008, a 46-year-old man presented to our hospital with swelling and progressively worsening pain on the lateral aspect of his right distal femur. He had undergone 4 procedures at another hospital to manage a GCT of bone and its recurrence, 16 to 23 years previously. The patient first underwent curettage and bone grafting at the age of 24. The tumour recurred 2 years later and the procedure was repeated. The tumour again recurred, 3 years later, and was managed with curettage, cryotherapy, and the insertion of hydroxyapatite. He was followed up for 10 years and remained disease-free for 16 years.
A clinical examination demonstrated no clicks, meniscus signs, or evidence of joint instability, but a mildly limited passive range of motion. Radiography and computed tomography showed an osteolytic lesion in his right distal femur destroying the cortex adjacent to the hydroxyapatite (Fig. 1) . The tumour gave a hypointense signal relative to the muscles on T1-weighted images, and a heterogeneously high signal on T2-weighted and T1-weighted enhanced images, and showed lateral soft-tissue involvement ( Fig. 1) .
The patient underwent an en bloc resection (from the epiphysis to adjacent metaphysis) with an adequately wide margin, and a reconstruction with a prosthesis. The resected tumour measured 10x6x5 cm. The hydroxyapatite in the cavity was not ossified (Fig. 2) . Histologically, the tumour consisted of mainly multi-nucleated giant cells with a cystic area (a secondary aneurysmal change) in the lateral portion (Fig. 3) . A diagnosis of a giant cell tumour with a secondary aneurysmal bone cyst was confirmed. At the one-year follow-up, there was no evidence of recurrence or metastasis.
DISCUSSION
GCT of bones account for around 4 to 5% of all primary bone tumours, and approximately 20% of benign primary bone tumours. 1 The peak incidence is seen in the 20 to 45 years age group, and there is a slight female predominance. 1 It usually affects the ends of long bones (involving the epiphysis and adjacent metaphysis), especially the distal femurs, proximal tibia, distal radius, and proximal humerus.
1 Local recurrence is associated with a 20% to 50% increased risk of benign pulmonary metastases. 1, 13 25% of recurrences occur within 6 months, 97% within 2 years, and 100% during the first 3 years. 1, 2 In one reported series, 128 of 384 patients developed recurrence at 0 to 90 months and none after 10 years. 12 Only 1% had a late recurrence. 3 In 9 cases of GCT of bones reported as recurring after 10, 6 10, 7 11, 5 12, 8 13, 4 19, 3 20, 3 27, 3 and 30 3 years, 5 were treated with curettage alone and one with a wide resection. [3] [4] [5] Treatments for GCT of bones include curettage, curettage and bone-grafting, 11, 12 curettage and burring, [10] [11] [12] cryotherapy of the cavity after curettage, 11, 12, 14, 17, 18 application of phenol, alcohol, and H 2 O 2 after curettage, 2, 11, 12, 16 insertion of methylmethacrylate cement in the cavity after curettage, 9, 11, 12, 15, 18, 19 insertion of hydroxyapatite, 11, 12 and resection followed by an allograft or prosthetic reconstruction. 11, 12 The local recurrence rates are high after curettage without adjuvant treatment (Table  1) , probably due to incomplete tumour removal. Intralesional curettage with adjuvant treatment (using phenol or liquid nitrogen, and/or filling the defect with methylmethacrylate cement) is therefore recommended. 2, 9, [11] [12] [13] [14] [15] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Local recurrence rates are higher in tumours in the distal radius, recurrent tumours, pathological fractures, tumour extension (T2), Campanacci grade III, intralesional margin, and where there has been curettage without adjuvant therapy. [10] [11] [12] 20, 22 Nonetheless, adjuvant treatment renders some risk factors (recurrence of tumour, pathological fracture, and Campanacci grade III) no longer significant. 11, 12 Adjuvant treatment correlates negatively to local recurrence.
Including our patient, there have been reports of only 4 men and 3 women aged 40 to 54 with late recurrence of giant cell tumours of bone after 11 to 30 years (Table 2) .
3-5 60% had local recurrence after curettage and cementation, compared to 0% after a wide resection. There are no clinical or histological differences between late and conventional recurrences of GCT of bone.
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Other studies 2, 9, [11] [12] [13] [14] [15] 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Curettage without adjuvant treatment 49% 34% 
